Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

51.62 -0.26 (-0.50%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crispr Therapeutics Ag

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
29 30 Next >
After Doubling in the Past 6 Months, Is This Stock a Buy?
This company has had a solid year, but there is still plenty of work ahead. 
Via The Motley Fool
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?
Crispr and Vertex are working toward the first submissions for a CRISPR-based product. 
Via Investor's Business Daily
2 No-Brainer Biotech Stocks to Buy Right Now
Vertex Therapeutics and Amgen have the building blocks for long-term success. 
Via The Motley Fool
3 Cathie Wood Stocks That Could Make Big Comebacks in 2023
These businesses aren't in as much trouble as their stock returns suggest that they are. 
Via The Motley Fool
3 Growth Stocks That Are Screaming Buys in December
Don't let these companies pass you by the next time you go stock shopping. 
Via The Motley Fool
What 5 Analyst Ratings Have To Say About CRISPR Therapeutics
Via Benzinga
Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock
Both stocks are heading for double-digit gains this year. 
Via The Motley Fool
3 Beaten-Down Stocks That Could Explode Higher in 2023
These stocks could have significant upside opportunities ahead. 
Via The Motley Fool
7 Stocks to Add to Your 10x Watchlist
It’s always a good time to look for stocks with exceptional growth potential. Here are seven 10x stocks for your watchlist. 
Via InvestorPlace
3 Growth Stocks With More Potential Than Any Cryptocurrency
If the crypto meltdown has you discouraged, don't give up on stocks. 
Via The Motley Fool
3 Red-Hot Stocks That Could Continue to Beat the Market
The success these stocks achieved in 2022 could be just the beginning. 
Via The Motley Fool
Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Want to Be Ready For a New Bull Market? Do These 3 Things Soon
It's easier to make money in bull markets when you've done the prep work beforehand. 
Via The Motley Fool
2 Growth Stocks That Could Help Set You Up for Life
Many growth stocks are down, but they're not all out. 
Via The Motley Fool
5 Best Bargain Stocks to Buy Before 2023
It's time to hit the best sale in town, and that involves many top stocks. 
Via The Motley Fool
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
The three companies are changing the pharmaceutical industry. 
Via The Motley Fool
Is CRISPR Therapeutics a Buy?
A strong cash position could offset some of the near-term risks that come with owning the biotech. 
Via The Motley Fool
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
-Clinical Data Due Next Week at ASH- 
Via Benzinga
2 Unstoppable Growth Stocks to Buy in 2022 and Beyond
These biotech players beat the bear market this year. 
Via The Motley Fool
3 Fierce Stocks That Are Screaming Buys in December
Here are three winners in the making. 
Via The Motley Fool
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
The company has already made plenty of investors happy. 
Via The Motley Fool
Bear Market Bargain Hunting: 3 Top Stocks to Buy Before 2023
These top players are ripe for recovery -- and long-term growth. 
Via The Motley Fool
3 Growth Stocks That Are Too Cheap to Ignore
Overlooking these stocks in the current market could be a mistake. 
Via The Motley Fool
Cathie Wood Has Bet Big On These 10 Stocks; Here's How They're Performing
Here's how Ark Invest's top holdings have performed in 2022. 
Via Investor's Business Daily
2 Stocks Near 52-Week Highs That Could Climb Higher
This pair of stocks are bucking the trend and they could climb even higher. 
Via The Motley Fool
Cathie Wood Is Selling This High-Flying Stock. Here's Why You Should Buy It Instead
The ARK Invest founder might regret trimming her position in this biotech stock. 
Via The Motley Fool
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 
Via Benzinga
Where Will Editas Medicine Be in 1 Year?
The company could continue lagging the market for a while. 
Via The Motley Fool
2 Growth Stocks That Could Double in 2023
Both are lagging the market this year. 
Via The Motley Fool
Crispr Therapeutics Stock: Bull vs. Bear
Crispr shares have fallen about 20% so far this year. 
Via The Motley Fool
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.